# Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

> **NCT01848925** · PHASE1 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **BIOLOGICAL:** SANGUINATE™
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT01848925
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848925, "Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01848925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*